In Vivo Tumor Delivery of a Recombinant Single-Chain Fv::Tumor Necrosis Factor:  A Fusion Protein

2002 ◽  
Vol 13 (1) ◽  
pp. 7-15 ◽  
Author(s):  
Stephen P. Cooke ◽  
R. Barbara Pedley ◽  
R. Boden ◽  
Richard H. J. Begent ◽  
Kerry A. Chester
Keyword(s):  
Tumor Necrosis Factor ◽  
Fusion Protein ◽  
Tumor Necrosis ◽  
Single Chain ◽  
Single Chain Fv ◽  
Tumor Delivery ◽  
Necrosis Factor

scholarly journals In Vivo Tumor Delivery of a Recombinant Single Chain Fv::Tumor Necrosis Factor-α Fusion Protein

2002 ◽  
Vol 13 (2) ◽  
pp. 385-385 ◽  
Author(s):  
Stephen P. Cooke ◽  
R. Barbara Pedley ◽  
R. Boden ◽  
Richard H. J. Begent ◽  
Kerry A. Chester
Keyword(s):  
Tumor Necrosis Factor ◽  
Fusion Protein ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Single Chain ◽  
Single Chain Fv ◽  
Tumor Delivery ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer

2019 ◽  
Author(s):  
Davor Bajic ◽  
Kerry A. Chester ◽  
Dario Neri
Keyword(s):  
Colorectal Cancer ◽  
Tumor Necrosis Factor ◽  
Fusion Protein ◽  
Mammalian Cells ◽  
Tumor Necrosis ◽  
Human Antibody ◽  
Single Chain ◽  
Single Chain Fv ◽  
Immunocompetent Mice ◽  
Necrosis Factor

ABSTRACTWe have cloned and characterized a novel fusion protein (Sm3E-TNF), consisting of the monoclonal antibody Sm3E in single-chain Fv fragment format, fused to murine tumor necrosis factor. The protein, which was expressed in mammalian cells and purified as a non-covalent stable homotrimer, bound to the cognate carcinoembryonic antigen (CEA) and retained tumor necrosis factor activity. A quantitative biodistribution experiment, performed in immunocompetent mice with CT26 colon carcinomas transfected with human CEA, revealed that Sm3E-TNF was able to preferentially accumulate in the tumors with excellent selectivity (tumor:blood ratio = 56:1, twenty-four hours after intravenous administration). The fusion protein mediated a rapid hemorrhagic necrosis of a large portion of the tumor mass, but a rim survived and eventually regrew. Surprisingly, the combination of Sm3E-TNF with 5-fluorouracil led to a reduction of therapeutic activity, while a combination with oxaliplatin led to a prolonged stabilization, with complete tumor eradication in 40% of treated mice. These therapy results were confirmed in a second immunocompetent mouse model of colorectal cancer (CEA-transfected C51 tumors) and provide a rationale for the possible clinical use of oxaliplatin in combination with fully-human antibody-TNF fusions.

scholarly journals Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo.

1987 ◽  
Vol 262 (17) ◽  
pp. 8390-8394 ◽  
Author(s):  
H Semb ◽  
J Peterson ◽  
J Tavernier ◽  
T Olivecrona
Keyword(s):  
Tumor Necrosis Factor ◽  
Lipoprotein Lipase ◽  
Tumor Necrosis ◽  
Necrosis Factor

Production of recombinant tumor necrosis factor receptor/Fc fusion protein by genetically manipulated chickens

2008 ◽  
Vol 105 (5) ◽  
pp. 454-459 ◽  
Author(s):  
Kenji Kyogoku ◽  
Kazuhiro Yoshida ◽  
Hiroyuki Watanabe ◽  
Takashi Yamashita ◽  
Yoshinori Kawabe ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Fusion Protein ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Receptor ◽  
Fc Fusion Protein ◽  
Genetically Manipulated ◽  
Recombinant Tumor Necrosis Factor ◽  
Necrosis Factor

Chylomicron-bound LPS inhibits tumor necrosis factor-induced capillary leak in vivo

2004 ◽  
Vol 121 (2) ◽  
pp. 276
Author(s):  
A.L. Spitzer ◽  
G.P. Victorino ◽  
F. Kasravi ◽  
B. Curran ◽  
J. Chang ◽  
...  
Keyword(s):  
Tumor Necrosis Factor ◽  
Tumor Necrosis ◽  
Capillary Leak ◽  
Necrosis Factor
Sign in / Sign up

Export Citation Format

Share Document